Glitaray M 1 Plus Tablet PR is a combination oral hypoglycemic agent containing Glimepiride (1 mg) and Metformin (850 mg), indicated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class drug, stimulates pancreatic beta cells to increase insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily decreases hepatic glucose production and improves peripheral insulin sensitivity, enhancing glucose uptake by muscle tissues. The combination of these two agents provides complementary mechanisms to achieve better glycemic control in patients inadequately controlled by diet, exercise, and monotherapy. Glitaray M 1 Plus Tablet PR is designed for prolonged release, allowing for sustained therapeutic effects and improved patient compliance with once or twice-daily dosing. It is essential to monitor blood glucose levels regularly and adjust the dosage based on glycemic response and tolerability. Common side effects may include gastrointestinal disturbances such as nausea, diarrhea, and abdominal discomfort, which often subside with continued use. Hypoglycemia is a potential risk due to Glimepiride’s insulinotropic action, necessitating caution in patients with renal or hepatic impairment. Glitaray M 1 Plus Tablet PR should be used under medical supervision, with appropriate lifestyle modifications including diet and exercise to optimize diabetes management.